Drugs / Pediacel®
Pediacel®
also known as
DT5aP-IPV-Hib 5-component Pertussis vaccine · DTaP-IPV-Hib · Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib · DTaP-IPV-Hib Pentavalent Vaccine · Pediacel, Sanofi Pasteur MSD Ltd.
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01839188 | May 2013 → Mar 2014 | meningococcal infection, viral infectious disease | MCM Vaccines B.V. | Completed | No outcome recorded |
| Phase 3 | NCT00652951 | Apr 2008 → May 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00384059 | Oct 2006 → Oct 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00355654 | Sep 2006 → Sep 2007 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00343421 | Jul 2006 → Jun 2008 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00287092 | Feb 2006 → May 2007 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00871338 Comparator | Jun 2009 → Mar 2010 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05951725 Comparator | Aug 2023 → Apr 2025 overdue | — | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00990080 Comparator | May → Jul 2010 | — | Dalhousie University | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07354269 Comparator | Sep 2025 → Apr 2026 overdue | poliomyelitis | Sinovac Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 4 | NCT02447718 Comparator | Nov 2015 → Mar 2018 | acute lymphoblastic leukemia | Canadian Immunization Research Network | Completed | No outcome recorded |
| Phase 4 | NCT02002156 Background | Jun 2014 → Aug 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pediacel | “Pediacel® at 2 and 4 Months of Age Followed By One Dose of Infanrix™ IPV/Hib at 6 Months of Age” NCT00990080 ↗ |
| Known as | Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib | “Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib” NCT05951725 ↗ |
| Known as | DT5aP-IPV-Hib 5-component Pertussis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00287092 ↗ |
| Known as | DTaP-IPV-Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07354269 ↗ |
| Known as | DTaP-IPV-Hib Pentavalent Vaccine | “Phase IV Clinical Study Comparing the Immunogenicity and Safety of a Single-dose Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains (sIPV) in Adolescents and Adults...” NCT07354269 ↗ |
| Known as | Pediacel, Sanofi Pasteur MSD Ltd. | “Pediacel®, Sanofi Pasteur MSD Ltd.” NCT02002156 ↗ |
| Modality | Vaccine | “DT5aP-IPV-Hib 5-component Pertussis vaccine” NCT00287092 ↗ |
| Route | Intramuscular | “0.5 mL, IM” NCT00287092 ↗ |